HIMS LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of illegitimate products and the collaboration with Novo Nordisk [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy, which jeopardized patient safety and posed a risk to its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - Defendants are accused of failing to disclose that the communication with Novo Nordisk would not ensure a long-term collaboration for access to Wegovy for Hims subscribers [4]. - The complaint also claims that Hims misrepresented the approval of its compounded semaglutide products by Novo and made misleading statements about the availability of branded Wegovy alongside these products [4]. Group 3: Legal Representation - Bragar Eagel & Squire, P.C. is representing the investors in this class action lawsuit and encourages affected individuals to reach out for more information [5][6].